[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602568":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Receiving Neoadjuvant Chemotherapy for Ovarian Cancer",null,[12,13],"Other: Patient Reported Outcomes Assessment","Other: Cognitive and General Health Assessments",[15,22],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Patient Reported Outcomes Assessment","Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) will be used to assess patient reported outcomes.",[9],[20,21],"FACT-O","FACT-Cog",{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"Cognitive and General Health Assessments","* Rey Verbal Learning Test\n* Trail Making Test\n* Patient Health Questionnaire (PHQ-2)\n* Mini Mental State Exam (MMSE)\n* Controlled Oral Word Association Test of the Multilingual Aphasia Examination",[9],[27],{"name":28,"affiliation":29,"role":30},"Lisa Barroilhet, MD","UW Carbone Cancer Center","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Supportive Oncology","CONTACT","(608)263-6002","supportiveoncology@uwcarbone.wisc.edu",[38],{"facility":29,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":10},"RECRUITING","Madison","Wisconsin","53792","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-89.40123,43.07305,{"lat":49,"lon":48},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100602568","cognitive-impact-of-neoadjuvant-chemotherapy-for-ovarian-cancer-100602568",false,"NCT07125209","Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer","Inclusion Criteria:\n\n* Age 18 or older\n* Pathological diagnosis of suspected epithelial ovarian cancer; of note, patients with suspected epithelial ovarian cancer who are pending a pathological diagnosis\u002Fbiopsy may be enrolled onto the study ahead of their biopsy. If the biopsy result is later inconsistent with epithelial ovarian cancer, they will be removed from the study and replaced\n* Planned to received neoadjuvant chemotherapy with carboplatin and paclitaxel; alternatives to these agents including abraxane, docetaxel, cisplatin may be used if patients have a chemotherapy reaction or otherwise cannot receive carboplatin and paclitaxel per usual standard of care\n* Patients may be receiving bevacizumab and may receive PARP inhibitors as a maintenance treatment; those receiving any other targeted therapy will be excluded\n\nExclusion Criteria:\n\n* History of diagnosed cognitive impairment, including dementia\n* History of traumatic brain injury\n* English is not their primary language\n* Known hearing or visual impairment not corrected with hearing devices and glasses\u002Fcontacts\n* Upper extremity motor impairment that would impact ability to perform the Trail Making Test\n* Baseline Mini Mental State Exam (MMSE) score less than 18","FEMALE","18 Years",{"count":62,"type":63},18,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.",[67,68],"Ovarian Cancer","Cognitive Change","2026-04-29",{"date":71,"type":72},"2026-05-05","ACTUAL",{"date":74,"type":72},"2026-04-28",{"date":76,"type":63},"2027-12",{"name":5,"class":6},1]